Kornimate/medical-research-clean huggingface dataset:
interest of re-oxygenation after inhalation of 50% nitrous oxide / 50% oxygen premix in dental cares

Conditions: Dental Cares Under Kalinox's Inhalation

Summary: the usefulness of re-oxygenation after inhalation of 50% nitrous oxide and 50% oxygen premix (kalinox 170 bar) during dental care is studied and the pollution resulting from administration of kalinox is also investigated.


Eligibility criteria:
inclusion criteria: * from 1 year old * anxious or phobic patients * very young children requiring selective dental cares * mental deficient patients * asa 1 or asa 2 patients exclusion criteria: * asa 3 or asa 4 patients * contraindication linked to the experimental product * patients with mental disorder incompatible with the motory test * patients that have received anxiolytic treatment less than 2 hours before the dental care
a drug-drug interaction study of gk activator (2) and glyburide in patients with type 2 diabetes.

Conditions: Diabetes Mellitus Type 2

Summary: this study will assess the potential pharmacodynamic and potential pharmacokinetic interaction between gk activator (2) and glyburide, in type 2 diabetes patients not adequately controlled with glyburide as standard prescribed therapy. patients will enter the study taking a dose of glyburide (10-20mg po daily) as prescribed prior to study start. gk activator (2) 100mg bid will be added for 5 days. from days 6-12 patients will receive gk activator (2) monotherapy, and from day 13 gk activator (2) will be discontinued and glyburide treatment re-started. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, aged 18-75 years; * type 2 diabetes mellitus; currently on glyburide 10-20 mg/day for \>=3 months; * untreated, or taken off anti-diabetic or statin therapy \>=2 weeks before study start. exclusion criteria: * type 1 diabetes mellitus, or latent autoimmune diabetes in adults; * diabetic neuropathy, retinopathy or nephropathy; * patients treated with insulin or ppar gamma agonist with 6 weeks of screening.
a prospective, single-center, randomized, controlled study of sevelamer carbonate in the lipid metabolism and uric acid treatment of obesity-related glomerulopathy

Conditions: Obesity and Glomerulopathy

Summary: to observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (org) after 12 weeks of sevelamer carbonate treatment.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of obesity * diagnosed org by renal biopsy * ldl\>3.37mmol/l * proteinuria 0.5-3.5g/d * egfr (ckd-epi formula) \> 30ml/min exclusion criteria: * other concomitant renal diseases * endocrine or drug-induced obesity; * type 2 diabetes * eyes or obvious microscopic hematuria; * swallowing difficulty / severe gastrointestinal dysfunction * intestinal obstruction; * severe arrhythmia; * hypophosphatemia (\<0.7mmol/l); * allergic to sevelamer carbonate * unable to well cooperate * females who are in the period of gestation or lactation, or refuse to use contraception; * participated in other clinical trial of drug within three months
effect of high altitude exposure, acclimatization and re-exposure on lung water content by ultrasound

Conditions: Effect of High Altitude

Summary: prospective interventional trial in lowlanders evaluating effect of acute exposure, acclimatization and re-exposure to high altitude.

low altitude baseline measurements will be performed in santiago de chile, 520 m, over the course of 3 days. participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the atacama large millimeter array (alma) base camp located at 2900 m near san pedro de atacama, northern chile. participants will stay there for the next 7 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing physiological testing. daily transports from 2900 to 5050 m will be by car (1 h ride, one way). after the first 7 day altitude sojourn participants will return to the santiago area (520 m) for a 7 day recovery period. a second altitude sojourn cycle with an identical schedule as the one described above and a final low altitude stay of 3 days will follow. measurements on study subjects will be performed at baseline (lowland, santiago de chile), then at 2nd day of altitude exposure and 7th day at altitude before returning to lowland; those are repeated in the second altitude sojourn cycle. measurements will be conducted by qualified specialists using a portable ultrasound device.

Eligibility criteria:
inclusion criteria: * born, raised and currently living \<800m * no overnight stay at altitudes \> 1500m 4 weeks before the study exclusion criteria: * previous altitude intolerance to altitude \<3000m * pregnancy * health impairment, which requires regular treatment
evaluation of safety of contraloid acetate in patients with mild cognitive impairment due to alzheimer's disease

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease

Summary: patients with mild cognitive impairment due to alzheimer's disease (mci due to ad) are at high risk to develop alzheimer´s dementia. the therapeutic agent contraloid has the potential to influence the chronic neurodegenerative process of ad. as contraloid was so far only administered to healthy subjects, the rational of the proposed study is first to collect safety data in patients diagnosed with mci due to ad, as the absorption, distribution, metabolism and excretion processes may be altered by disease, aging, comorbidities and concomitant drug therapies. additionally, the design of a subsequent phase ii study will be based on the data of this study. the results of the exploratory analyses will enable power calculations and the identification of the most useful and reliable biomarkers for the subsequent proof of concept phase ii study.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with mci due to ad according to dsm-v 2. age between 50 and 80 years (male and female) 3. mmse score 22-30 4. written informed consent (according amg §40 (1) 3b) 5. level of aβ-oligomers: mind. 1fm 6. csf according to diagnosis (p-tau \> 62 pg/ml, total csf aβ 1-42/1-40 ratio ≤ 0.055) 7. 3 months prior to screening stable medication 8. females without childbearing potential exclusion criteria: 1. history of seizures 2. history of stroke or tia 3. unstable medical, neurological or psychiatric condition 4. current treatment with one of the following substances: * typical antipsychotic or neuroleptic medication within 6 months of screening * anti-coagulation medications within 3 months of screening * chronic use of opiates or opioids (including long-acting opioid medication) within 3 months of screening * stimulant medications (amphetamine, methylphenidate preparations, or modafinil) within 1 month of screening and throughout the study * chronic use of benzodiazepines, barbiturates, or hypnotics from 3 months before screening 5. persons who are legally detained in an official institution 6. persons who may be dependent on the sponsor, the investigator or the trial site 7. persons without caregiver 8. participation in other clinical trials according to amg (1 month before the time of this trial) 9. persons showing eeg abnormalities
study of oglemilast for the treatment of asthma

Conditions: Asthma

Summary: the purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.


Eligibility criteria:
inclusion criteria: * mild atopic asthma * hyperreactivity to methacholine * exhibit positive response to standard allergen skin prick test exclusion criteria: * pulmonary disease other than asthma * asthma exacerbation within 4 weeks * history of substance abuse * active cardiac disease

Keywords: oglemilast asthma allergen prevention prophylaxis allergen-induced asthma
ghrelin - a possible opportunity to improve appetite

Conditions: Cancer

Summary: the study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.

randomized study with follow up evaluations each month until preterminal state. cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.

Eligibility criteria:
inclusion criteria: * weight loss exclusion criteria: * diabetes

Keywords: ghrelin nutrition cancer patients survival
parameter changes in functional electrical stimulation

Conditions: Gait Disorders, Neurologic

Summary: this study aims to look at how changes to a person's functional electrical stimulation might change how they walk. functional electrical stimulation (fes) is commonly used to help people with foot drop from upper motor neurone conditions such as stroke or multiple sclerosis. this group of people have muscle weakness which makes it difficult to lift the foot, which causes trips and falls. fes reduces foot drop by using a portable device to apply short electrical pulses to the nerve which lifts the foot. the fes device stimulates this nerve only during the swing phase, when the foot is off the floor. typically this is achieved by using a foot-switch, which detects when the heel leaves the floor. stimulation begins a short interval of time after the heel leaves the floor, ramps up from zero to set stimulation for the individual, and at another period of time after the heel hits the floor, stimulation ramps down from set amount to zero. there are four time intervals described here which can be varied by the clinician on the device:- * delay (the time between heel lift and the start of stimulation) * ramp up (the time for stimulation to reach full strength) * extension (the time between heel strike and the ramp down) * ramp down (the time for stimulation to reach zero from full strength) these intervals are usually set by experienced clinicians using a qualitative assessment of the patient's walking and trial-and-error. a literature review has found no published studies which compare walking with different timing. this knowledge would be useful for clinicians, who could use this information as a starting point in finding the best timing parameters for each patient.


Eligibility criteria:
inclusion criteria: * upper motor neurone lesion causing foot drop * currently use single-channel odstock medical odfs functional electrical stimulator * age 18 or older * attending leeds fes service follow-up clinics exclusion criteria: * • fes user for less than three months * lower limb prosthesis * cannot walk 5m with walking aids * cannot walk twenty 5m walks within a three-hour period * use fes less than once per week
a study of galcanezumab (ly2951742) in participants 6 to 17 years of age with episodic migraine

Conditions: Episodic Migraine

Summary: the main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. the primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

the study has two parts which enroll separately from each other such that participants may choose to participate in either but not both: the main study and a study addendum. * the main study includes a 3-month, randomized, double-blind treatment period in which participants receive either galcanezumab or placebo, followed by a 9-month open-label extension in which all participants receive galcanezumab. * the study addendum is a stand-alone study of galcanezumab pharmacokinetics and safety in a group of participants separate from those in the main study. the study addendum includes a 5-month evaluation period after a single injection of galcanezumab, followed by a 9-month open-label extension.

Eligibility criteria:
inclusion criteria: * have a diagnosis of migraine with or without aura as defined by the ihs ichd-3 guidelines (1.1 or 1.2 according to ichd-3 \[2018\]), with a history of migraine headaches of at least 6 months prior to screening. exclusion criteria: * participants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline. * known hypersensitivity to monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients. * current use or prior exposure to galcanezumab, another cgrp antibody, or cgrp receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a cgrp antibody. * history of ihs ichd-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine). * history of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury. * participants with a known history of intracranial tumors or developmental malformations including chiari malformations.

Keywords: pediatric children prevention prophylaxis headache pediatric migraine
a study of the safety and efficacy of single-agent carlumab (an anti-chemokine ligand 2 [ccl2]) in participants with metastatic castrate-resistant prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of sperm).

this is an open-label (all people know the identity of the intervention), multicenter trial (conducted in more than one center) in participants with metastatic castrate-resistant prostate cancer. the trial consists of 3 phases: screening period, treatment period of approximately 4 months, and a follow-up period (week 1, 4, 8 and 12 after the last dose) of up to 12 weeks after the administration of last dose. the participants will receive carlumab at the dose of 15 milligram/kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression. efficacy of the participants will be primarily evaluated by composite response. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * histological documentation of adenocarcinoma of the prostate * received at least 1 but no more than 2 prior docetaxel-based chemotherapy regimens and had disease progression following the last therapy * serum prostate specific antigen (psa) greater than or equal to 5.0 nanogram/milliliter (ng/ml) within 4 weeks prior to the first dose of study agent * orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram/deciliter by means of pharmacological/chemical castration within 4 weeks prior to the first dose of study agent * at least 6 weeks from prior docetaxel chemotherapy regimen to first dose of study agent exclusion criteria: * experience a hormonal treatment withdrawal response (including a lowering of psa that was previously rising or symptomatic improvement) * known or symptomatic central nervous system metastases * residual toxicities resulting from previous therapy that are grade 2 or more (except for alopecia) * known allergies, hypersensitivity, or intolerance to carlumab or its excipients or clinically significant reactions to chimeric or human proteins * vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study agent

Keywords: prostate cancer infusion carlumab cnto 888
hyper-cvad treatment of adult t-cell acute lymphoblastic leukemia in sweden.

Conditions: T-cell Acute Lymphoblastic Leukemia

Summary: hyper-cvad (a chemotherapy regimen) has shown promising results in adult t-cell acute lymphoblastic leukemia (t-all). patients with t-all diagnosis were reported to the swedish adult acute leukemia registry between october 2002 and september 2006. hyper-cvad was recommended to all patients without severe comorbidity. allogeneic stem cell transplantation was recommended for patients with high-risk disease. the aim of this population-based study was to assess the efficacy of hyper-cvad treatment.

patients with t-all diagnosis were prospectively reported to the swedish adult acute leukemia registry between october 2002 and september 2006. missing data were complemented retrospectively. hyper-cvad (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of high-dose methotrexate and cytarabine) was recommended to all patients without severe comorbidity. allogeneic stem cell transplantation (sct) was recommended for patients with high-risk disease: white blood cell count \>100×109/l, complete remission (cr) achievement after more than two courses, high minimal residual disease level, and relapsed disease (after cr2 achievement). in patients without high-risk factors maintenance therapy was given with per oral mercaptopurine and methotrexate for two years including reinduction courses: daunorubicine, vincristine and prednisolone every second month (1st year) and cytarabine, thioguanine and prednisolone every third month (2nd year).

Eligibility criteria:
inclusion criteria: all patients with t-all diagnosis exclusion criteria: no

Keywords: t-cell acute lymphoblastic leukemia chemotherapy allogeneic stem cell transplantation
upper extremity lymphatic mapping for breast cancer patients

Conditions: Breast Cancer; Axillary Lymph Node Dissection

Summary: this study is being done to see if lymph nodes that drain the arm also drain the breast. an axillary lymph node dissection removes lymph nodes under the arm. it is done to help prevent cancer cells from spreading to the rest of the body. usually, about 12 to 15 nodes are removed. they are then examined to see if they have cancer cells. removing these lymph nodes has some side effects. the most common is lymphedema. this is the build-up of fluid in the arm. this study will tell us if it may be possible in the future to identify lymph nodes that just drain the arm. leaving those nodes may help to reduce the rate of lymphedema for future patients.


Eligibility criteria:
inclusion criteria: * females with stage ii invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration who are scheduled to undergo an alnd. * females \> 21 years of age exclusion criteria: * prior ipsilateral axillary surgery * prior ipsilateral axillary radiation * prior ipsilateral breast cancer * prior ipsilateral breast radiation * allergy to isosulfan blue dye * history of ipsilateral upper extremity lymphedema * prior history of surgical excision of the upper outer quadrant of the ipsilateral breast * prior history of neoadjuvant chemotherapy for current breast cancer * bulky axillary disease at presentation (n2)

Keywords: breast lymph nodes
comparison of the evaluation of cad by ct angioscan and coronary angiogram

Conditions: Coronary Artery Disease

Summary: the use of ct coronary angioscan (ct-as) is gaining popularity, but its exact value as evaluation of cad requires confirmation. we intend to compare the results of ct-as and convention coronary angiogram results in patients who are scheduled for an ascending aorta aneurysm reparation surgery. these examens are standard of care before this surgery, so there is no additional danger or disadvantage for the patient. we hope to confirm that ct-as is a reliable screening test for cad in patient undergoing heart surgery for other reason than cad.


Eligibility criteria:
inclusion criteria: * ascending aorta aneurysm waiting for surgical correction * willing to participate * needing a coronary angiogram and a ct-as for medical reasons exclusion criteria: * refuse to participate * allergy to contrast material * incomplete results or having one of the test done in another hospital * arrythmia * more than 6 months between the two exams
goal directed fluid administration for kidney transplantation

Conditions: End Stage Renal Disease

Summary: the goal of the proposed study is to evaluate the efficacy of a goal-directed fluid administration algorithm on early graft function in patients undergoing kidney transplantation. fluid administration has increasingly been scrutinized within anesthesia related literature as an area for improvement, and the imbalance present between estimated blood loss and total fluid administered for kidney transplants must be amongst the highest case categories. considering the patients are anuric for the majority of the procedure, unguided administration of multiple liters of crystalloid appears antiquated.


Eligibility criteria:
inclusion criteria: * end stage renal disease requiring dialysis * age \>18y * normal cognitive function. exclusion criteria: * severe left ventricular dysfunction (ef\<50%) * known cardiomyopathy * symptomatic cad known valvular disease * severe anemia (hgb\<7.0) * patients with prior transplants o * patients who suffered surgical complications as communicated by the surgical team. we chose these exclusion criteria to prevent enrolling patients who would not tolerate aggressive hydration possible in the treatment group. the exclusion criteria may be excessively restrictive, however, given the current practice that frequently results in rapid large volume loading without a monitor of intravascular volume status.

Keywords: kidney transplantation
gpnmb-targeting chimeric antigen receptor t-cell therapy (gcar1) for a patient with alveolar soft part sarcoma

Conditions: Alveolar Soft Part Sarcoma

Summary: clic-yyc-gpnmb-01 is a single patient study (sps) developed according to the health canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there are no options of treatment or cure remaining. the patient under consideration for clic-yyc-gpnmb-01 has progressive metastatic alveolar soft part sarcoma (asps). the investigators propose to treat the patient with gcar1, a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (car) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic b (gpnmb).


Eligibility criteria:
inclusion criteria: 1. completion of informed consent form exclusion criteria: 1. any significant medical issue(s) that would, in the opinion of the principal investigator (pi), prevent this patient from being dosed.